Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design

Jim Zhen Wu*, Chin-chung Lin and Zhi Hong

Drug Discovery and Development, Ribapharm Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626, USA

Keywords: ribavirin, viramidine, hepatitis C virus, HCV, prodrugs

The epidemics caused by pathogenic viruses, such as HIV, hepatitis C virus (HCV) and most recently the severe acute respiratory syndrome (SARS) by a new coronavirus, represent major global health hazards, which demand novel broad-spectrum antiviral intervention. Although discovered 40 years ago, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) remains the only approved small molecule drug that is active against both DNA and RNA viruses. The unique antiviral profile of ribavirin deserves a brief review of its discovery. Back in the 1960s, two five-membered ring nucleoside antibiotics, showdomycin and pyrazomycin, were isolated from bacterial culture, and both (Figure 1) showed significant activity against a broad series of viruses in cell culture. The novel properties of these nucleoside antibiotics prompted synthesis and testing of a number of imidazole- and triazole-based ribonucleosides. Among them, ribavirin (originally termed Virazole) stood out as the most promising broad-spectrum antiviral agent. Structurally, ribavirin is a ribonucleoside with an unconventional triazole base (Figure 1). X-ray crystallographic studies indicated that the five-membered triazole ribonucleoside is capable of mimicking the conformation of several canonical purine ribonucleosides with its 3-carboxamide oxygen and nitrogen spatially eclipsing the O6 and N1 atoms of inosine and guanosine. By rotating the C3′-C6 bond by 180°, ribavirin also resembles the conformation of adenosine. The multiple conformations adopted by ribavirin make it possible to target both viral and host enzymes that utilize purine ribonucleosides/nucleotides as a substrate or a cofactor, and may hold the key for its broad-spectrum antiviral activity. Current data support the notion that ribavirin acts by pleiotropic modes of action. Ribavirin itself is a produg that is metabolized to the active 5′-monophosphate,-diphosphate and -triphosphate in vivo. Ribavirin 5′-monophosphate (RMP) inhibits cellular inosine monophosphate dehydrogenase (IMPDH), thereby depleting intracellular pools of GTP for viral replication. Ribavirin 5′-triphosphate (RTP) is the major metabolite accumulated in vivo. It is an effective inhibitor of viral RNA guanylyl transferase and (guanine-5′-N′)-methyl transferase, contributing to the defective 5′-cap structure of viral transcripts and insufficient translation. All the 5′-phosphate forms of ribavirin have been implicated as direct inhibitors of viral RNA polymerases. As a nucleotide analogue, RTP can also be incorporated into a viral genome and induces virus error catastrophe by mutations. In a recent study of poliovirus replication in cell culture, a single mutation in the poliovirus RNA-dependent RNA polymerase was shown to confer resistance to ribavirin. This is the first report of viral resistance to ribavirin. This study reinforces the notion that the transition mutations caused by incorporation of ribavirin as a mutagen are responsible for antiviral activity, at least in the case of poliovirus. On the other hand, consistent with the broad-spectrum antiviral property, ribavirin is also a small molecule immunomodulator and is capable of eliciting immuno-based antiviral activities by shifting the host immune response to ‘type 1’, thereby enhancing T cell mediated immunity that favours elimination of intracellular viral pathogens. The fact that no ribavirin resistance has been convincingly identified in the clinical setting supports the notion that ribavirin exerts its effect through non-specific or pleiotropic mechanisms.

Despite its success as an effective antiviral in cell culture and in animal infection models, the clinical application of ribavirin has so far met with mixed results. One factor that may limit its clinical potential is the dose-limiting haemolytic anaemia when high doses are administered. Ribavirin formulated as small particle aerosol is currently approved for treatment of the respiratory syncytial virus (RSV) infection. In capsule or tablet form it is used as a part of combination therapy for chronic HCV infection. Notably, the combination therapy of ribavirin with interferon-alpha (both native and pegylated forms) has become the ‘gold’ standard for anti-HCV chemotherapy.

For the treatment of HCV infection, combination therapy suffers somewhat from the side effect of haemolytic anaemia caused by the accumulation of RTP in red blood cells (RBCs). This results in dose reduction or discontinuation of therapy in a proportion of patients. In an attempt to deliver ribavirin more specifically to the liver and reduce the trapping of ribavirin metabolites in RBCs, thereby improving the therapeutic index, a number of ribavirin derivatives have been explored. One emerging compound is the 3-carboxamidine derivative of ribavirin, viramidine (previously known as riamidine) (see Figure 3). As one of the compounds related to ribavirin by structure–activity relationship studies, it exhibits in vitro antiviral and immunomodulation activities comparable to ribavirin. Recent biochemical and pharmacokinetic studies have shown that viramidine acts as a prodrug of ribavirin and has very different pharmacokinetic properties from its parent compound. Possibly as a result of
its positively charged 3-carboxamidine group, viramidine does not transport into RBCs efficiently. Animal studies indicate that viramidine has a better liver targeting property than ribavirin and the liver is thought to be the main conversion site of the prodrug. As illustrated by the quantitative whole body autoradiography of rats (Figure 2), there is more radiolabelled drug trapped in the liver after the oral dosing of [14C]viramidine compared with that of [14C]ribavirin. Further studies in monkeys suggest that viramidine yields three times more drug in the liver but only half of the drug level in RBCs compared with ribavirin. Because of this preferential liver targeting property and the concomitant reduction in the haemolytic potential, viramidine appears to be a safe alternative to ribavirin, and it may provide many clinical benefits to HCV patients. It is currently in a Phase II clinical trial for the active chronic HCV infection.

To understand the metabolic conversion of viramidine into ribavirin and gain knowledge of prodrug design, we have investigated the enzymic mechanism of viramidine deamination. Based on the structural similarity of viramidine to adenosine, adenosine deaminase (ADA) was believed to be the potential enzyme that catalyses the conversion. ADA catalyses the hydrolytic deamination of adenosine to inosine and ammonia and is a key enzyme in purine metabolism. Using a UV spectroscopic method, we discovered that ADA indeed catalyses the conversion of viramidine into ribavirin in vitro. The enzymic reaction has a catalytic efficiency of 0.19 mM$^{-1}$ s$^{-1}$ in a PBS buffer of pH 7.3. Interestingly, by shifting the buffer's pH from 7.3 to 9.5, the catalytic efficiency is increased by 320-fold to 61 mM$^{-1}$ s$^{-1}$ with a $K_m$ of 0.46 mM and a $k_{cat}$ of 28 s$^{-1}$. Compared with the deamination of adenosine, this reaction has an unusually high optimal pH of 10. This optimal pH coincides with the $pK_a$ of the 3-carboxamidine of viramidine, implying that viramidine first undergoes deprotonation before deamination. Previous studies reported that ribavirin is deaminated in vivo to a carboxylic derivative, ICN3297, a metabolite that does not possess any antiviral activity (Figure 3a). Therefore, we further investigated the possibility that ADA catalyses another round of deamination, converting ribavirin into ICN3297. This deamination is very slow with a catalytic efficiency of 0.037 mM$^{-1}$ s$^{-1}$ at the optimal pH of 7.3. Although this study cannot rule out the participation of other enzymes in metabolizing viramidine, it nevertheless suggests that ADA is a strong candidate for the conversion in vivo. These experiments also reveal the unusual propensity of ADA to catalyse two consecutive deamination reactions on a single substrate by first
hydrolysing viramidine, and then slowly converting ribavirin into an inactive metabolite (Figure 3a).

An enzyme-activated prodrug approach is a strategy widely employed to improve absorption, bioavailability and target specificity of potential therapeutic agents in order to minimize adverse side effects. ADA is an ideal enzyme for prodrug activation because of its ubiquitous presence in human tissues and its enormous catalytic capability. Indeed, many examples of ADA-activated purine nucleoside prodrugs have been reported (Figure 3b). For example, the 6-amino prodrug of antiherpetic aciclovir has been reported for improvement of absorption through the gut to attain higher plasma levels. Similarly, the 6-amino derivative of 2',β-fluoro-2',3'-dideoxyinosine (F-ddI) or 2',3'-dideoxyinosine (ddI) was prepared as a more acid-stable prodrug for central nervous delivery. 2,6-Diaminopurine dioxolane is currently in clinical trials as a more water-soluble and bioavailable prodrug of guanine dioxolane for treatment of HIV infection. Viramidine is the only example of an ADA-activated prodrug that possesses a non-cognate five-membered triazole base in the place of a purine.

An enzyme-activated prodrug approach is a strategy widely employed to improve absorption, bioavailability and target specificity of potential therapeutic agents in order to minimize adverse side effects. ADA is an ideal enzyme for prodrug activation because of its ubiquitous presence in human tissues and its enormous catalytic capability. Indeed, many examples of ADA-activated purine nucleoside prodrugs have been reported (Figure 3b). For example, the 6-amino prodrug of antiherpetic aciclovir has been reported for improvement of absorption through the gut to attain higher plasma levels. Similarly, the 6-amino derivative of 2',β-fluoro-2',3'-dideoxyinosine (F-ddI) or 2',3'-dideoxyinosine (ddI) was prepared as a more acid-stable prodrug for central nervous delivery. 2,6-Diaminopurine dioxolane is currently in clinical trials as a more water-soluble and bioavailable prodrug of guanine dioxolane for treatment of HIV infection. Viramidine is the only example of an ADA-activated prodrug that possesses a non-cognate five-membered triazole base in the place of a purine.

An enzyme-activated prodrug approach is a strategy widely employed to improve absorption, bioavailability and target specificity of potential therapeutic agents in order to minimize adverse side effects. ADA is an ideal enzyme for prodrug activation because of its ubiquitous presence in human tissues and its enormous catalytic capability. Indeed, many examples of ADA-activated purine nucleoside prodrugs have been reported (Figure 3b). For example, the 6-amino prodrug of antiherpetic aciclovir has been reported for improvement of absorption through the gut to attain higher plasma levels. Similarly, the 6-amino derivative of 2',β-fluoro-2',3'-dideoxyinosine (F-ddI) or 2',3'-dideoxyinosine (ddI) was prepared as a more acid-stable prodrug for central nervous delivery. 2,6-Diaminopurine dioxolane is currently in clinical trials as a more water-soluble and bioavailable prodrug of guanine dioxolane for treatment of HIV infection. Viramidine is the only example of an ADA-activated prodrug that possesses a non-cognate five-membered triazole base in the place of a purine.

An enzyme-activated prodrug approach is a strategy widely employed to improve absorption, bioavailability and target specificity of potential therapeutic agents in order to minimize adverse side effects. ADA is an ideal enzyme for prodrug activation because of its ubiquitous presence in human tissues and its enormous catalytic capability. Indeed, many examples of ADA-activated purine nucleoside prodrugs have been reported (Figure 3b). For example, the 6-amino prodrug of antiherpetic aciclovir has been reported for improvement of absorption through the gut to attain higher plasma levels. Similarly, the 6-amino derivative of 2',β-fluoro-2',3'-dideoxyinosine (F-ddI) or 2',3'-dideoxyinosine (ddI) was prepared as a more acid-stable prodrug for central nervous delivery. 2,6-Diaminopurine dioxolane is currently in clinical trials as a more water-soluble and bioavailable prodrug of guanine dioxolane for treatment of HIV infection. Viramidine is the only example of an ADA-activated prodrug that possesses a non-cognate five-membered triazole base in the place of a purine.
to ADA is visualized (Figure 3c). Evidently, ADA initiates hydrolytic deamination with Asp^{296} acting as a general base to assist the zinc-bound water molecule for a nucleophilic attack at the C6 position of adenosine. Substrate recognition commands non-specific hydrophobic interaction as well as specific interactions. For adenosine, N1, N3 and N7 of the purine ring form three individual hydrogen bonds for the purine and the two with the 5′-hydroxy groups of the ribose interact with an ordered active-site water molecule. In addition, the 3′-hydroxy forms a hydrogen bond with Asp^{19}. Since dideoxynucleosides can be utilized as a substrate for ADA, these three hydrogen bonds are likely to be insignificant for substrate recognition. However, the 5′-hydroxy appears to play a key role in the ribose recognition, since it interacts with both His^{15} and Asp^{19} through a hydrogen bond (Figure 3c). Based on the structural analysis, ADA should tolerate major structural alteration on the ribose but less on the purine. To design a sound prodrug, the three specific hydrogen bonds for the purine and the two with the 5′-hydroxy should be preserved. This conclusion is consistent with the structural features of the known prodrugs. As illustrated in Figure 3(b), all the known prodrugs have an intact purine and an equivalent 5′-hydroxy group. Of all the ADA-activated prodrugs, viramidine is the only one that misses the critical N3-Gly^{184} hydrogen bond and this explains the very high $K_v$ value for viramidine. Nevertheless, the fact that viramidine is an ADA-activated prodrug suggests that it is possible to design a prodrug by employing a non-cognate five-membered ring base in the place of purine, providing most of the critical interactions are conserved.

With the availability of much biochemical and structural information on ADA, it is relatively straightforward to design an ADA-activated nucleoside prodrug. However, the first and daunting task is to discover a broad-spectrum antiviral nucleoside in the first place. Compared with the pervasive nucleotide prodrug design that is focused on the modification of 5′-phosphate for in vivo delivery, ADA-activated prodrugs possess novel pharmacokinetic properties. The verification of the ADA-catalysed viramidine conversion into ribavirin has opened a new chapter to design novel and organ-specific ADA-activated nucleoside prodrugs for antiviral and anticancer chemotherapy.

References


